Dermatomyositis(DM) is an autoimmune disease with skin and muscle involvement to varying extents. With its recalcitrance standard-of-care treatments for some, more treatment options are needed. Clinical trials use outcome measures assess activity, such as the CDASI-activity(CDASI-A) or Investigator’s Global Assessment(IGA) scores cutaneous in DM. To be clinically useful, must demonstrate respon...